Effect of Dapsone gel 5% in the treatment of patients with acne vulgaris

Comparative evaluation of Dapsone gel 5% with Adapalene gel 0.1% in patients with acne vulgaris

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230806059062N1

Enrollment

Registered

2023-08-20

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne. Acne vulgaris

Interventions

Intervention 1: Intervention group: Treatment with 5% dapsone gel (Pars Behrouzan Jam Company) twice a day for 2 months. Intervention 2: Intervention group: Treatment with Adapalene gel 0.1 % (Razak C

Eligibility

Sex/Gender

All

Age

12 Years to 30 Years

Inclusion criteria

Inclusion criteria: Patients with moderate to severe inflammatory acne on the face

Exclusion criteria

Exclusion criteria: Pregnant and lactating women History of using systemic anti-acne treatment drugs in the previous 1 month The presence of inflammatory acne on the trunk without facial involvement Cases of mild acne (the presence of only comedones without inflammatory lesions) Photosensitivity Patients receiving drugs that cause photosensitivity (such as griseofulvin). Age above 30 years and below 12 years Patients with G6pd deficiency (in the group receiving dapsone gel) History of allergy to doxycycline, adapalene and dapsone

Design outcomes

Primary

Measure	Time frame
Acne severity based on the global acne grading system. Timepoint: Before starting treatment, 1, 2 and 3 months after starting treatment. Method of measurement: Global acne grading system.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKosar Gholipour

Ahvaz University of Medical Sciences

gholipour.k@ajums.ac.ir+98 61 3314 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026